Whether these latter type I IFNs are sufficiently potent to protect anti-IFN-α-treated SLE patients from serious complications during for instance a flu pandemic remains to be established, and this can only be addressed in larger clinical trials. Here, IFNA1 is linked to systemic lupus erythematosus.